The Trendlines Group

Non-IFRS value of the portfolio at the end of June 2023 was US$152.8 million

The nature of Trendlines' business means lumpy earnings and revenue, but CEO Todd Dollinger is telling investors to look beyond.

"We believe that our company is undervalued by the market."

Phytolon, a portfolio company of The Trendlines Group, has secured $14.5 million in its latest Series A funding.

The new shares represent 21.35% of the existing share capital in the company and 17.59% of the enlarged share capital

This investment will give Trendlines an internal rate of return of 165%.

The proposed listing on TASE was announced on April 5, after the company applied to the ISA to publish a prospectus on March 31.

Trendlines' minimum share of the sale proceeds is estimated at $19 mil.

Trendlines has exited portfolio company ApiFix, which focuses on non-fusion treatment of idiopathic scoliosis, particularly among adolescents.

SINGAPORE (Dec 13): While Israel-based The Trendlines Group sank into losses for 3QFY2019, its latest quarter, the company expects to be better positioned — with more resources, and time to grow the value of its portfolio of investments, following an in